Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Amgen has partnered with Adaptive Biotechnologies to develop a drug candidate that could prevent and treat Covid-19 coronavirus infection.
The partners will identify and develop fully human neutralising antibodies that act on SARS-CoV-2. As part of the alliance, Adaptive’s immune medicine platform to discover virus-neutralising antibodies will combine with Amgen’s immunology and antibody development expertise.
Neutralising antibodies protect healthy cells by hindering the biological function of the virus, noted Amgen. These antibodies can help treat infected patients and can also be given to individuals at high risk of exposure to the virus, such as